Spyre Therapeutics (SYRE) Change in Account Payables (2016 - 2025)
Historic Change in Account Payables for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $3.7 million.
- Spyre Therapeutics' Change in Account Payables rose 26778.67% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 13856.08%. This contributed to the annual value of -$16.0 million for FY2024, which is 56532.06% down from last year.
- Spyre Therapeutics' Change in Account Payables amounted to $3.7 million in Q3 2025, which was up 26778.67% from $23000.0 recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Change in Account Payables registered a high of $3.7 million during Q3 2025, and its lowest value of -$6.5 million during Q1 2024.
- Moreover, its 5-year median value for Change in Account Payables was -$335000.0 (2021), whereas its average is -$693052.6.
- As far as peak fluctuations go, Spyre Therapeutics' Change in Account Payables surged by 2920000.0% in 2021, and later crashed by 106807.87% in 2024.
- Spyre Therapeutics' Change in Account Payables (Quarter) stood at $1.5 million in 2021, then crashed by 340.55% to -$3.5 million in 2022, then soared by 91.8% to -$287000.0 in 2023, then tumbled by 193.73% to -$843000.0 in 2024, then skyrocketed by 544.25% to $3.7 million in 2025.
- Its Change in Account Payables was $3.7 million in Q3 2025, compared to $23000.0 in Q2 2025 and $3.0 million in Q1 2025.